High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis

Keyphrases

• High Dose 100%
• Fludarabine 100%
• Refractory Rheumatoid Arthritis 100%
• T Cells 50%
• CD4+ 33%
• Lymphopenia 33%
• Clinical Improvement 33%
• Body Surface Area 33%
• American College of Rheumatology Criteria 33%
• Swollen Joint Count 33%
• Interferon-α (IFN-α) 16%
• Open-label Trial 16%
• Intention-to-treat Analysis 16%
• Lymphocytes 16%
• Consecutive Days 16%
• B Cells 16%
• Interleukin-10 16%
• Tumor Necrosis Factor-α 16%
• Interleukin-2 16%
• Cell-to-cell 16%
• Tolerability 16%
• Peripheral Blood Lymphocytes 16%
• Regenerability 16%
• CD45RA 16%
• Naïve T Cells 16%
• 2-dose 16%
• Proliferative Response 16%
• Second-line Agents 16%
• Immunological Effects 16%
• Clinical Effect 16%
• Monocyte-derived Cells 16%
• Regeneration 16%
• Lymphocyte Function 16%
• Peripheral Blood Mononuclear Cells 16%
• Rheumatoid Arthritis 16%
• Herpes Zoster 16%
• Mitogen 16%
• CD45RO 16%
• % Response 16%
• Nucleoside Analogues 16%
• Phenotypic Analysis 16%
• Tender 16%
• Promising Drug 16%
• Memory CD4+ T Cells 16%
• Autoimmune Disease Treatment 16%
• Open-label Clinical Trial 16%
• Grater 16%
• Tender Joint Count 16%
• Antirheumatic Drugs 16%
• Cell Functional Assays 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Rheumatoid Arthritis 100%
• Fludarabine 100%
• Infection 33%
• Lymphocytopenia 33%
• Open-Label Trial 16%
• Cytokine 16%
• Tumor Necrosis Factor 16%
• Interleukin 2 16%
• Interferon 16%
• Clinical Trial 16%
• Tolerability 16%
• Glucocorticoid 16%
• Autoimmune Disease 16%
• Nucleoside Analog 16%
• Herpes Zoster 16%
• Mitogenic Agent 16%
• Antirheumatic Agent 16%